44
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Cyclosporin Pharmacokinetics after Intravenous and Oral Administration in Patients with Crohn's Disease

, , &
Pages 961-967 | Received 01 Mar 1992, Accepted 07 Jul 1992, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Teruo Murakami, Erik Bodor & Nicholas Bodor. (2020) Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 59-78.
Read now
J. Brynskov & S. Nørby Rasmussen. (1996) Clinical Pharmacology in Gastroenterology: Development of New Forms of Treatment of Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology 31:sup216, pages 175-180.
Read now
J. Brynskov. (1993) Cyclosporin for Inflammatory Bowel Disease: Mechanisms and Possible Actions. Scandinavian Journal of Gastroenterology 28:10, pages 849-857.
Read now

Articles from other publishers (21)

Nicole K. Wilson & Ann D. Kataria. (2023) Immunosuppression in solid organ–transplant recipients and impact on nutrition support. Nutrition in Clinical Practice.
Crossref
Angela EffingerMark McAllisterIrena TomaszewskaCaitriona M. O’Driscoll, Mark TaylorSteve GomersallJames HeatonKieran L. SmithInese SarcevicaSam L. YoungNikoletta Fotaki. (2021) Investigating the Impact of Crohn’s Disease on the Bioaccessibility of a Lipid-Based Formulation with an In Vitro Dynamic Gastrointestinal Model. Molecular Pharmaceutics 18:4, pages 1530-1543.
Crossref
Keshavamurthy Vinay, Akanksha Kaushik, Muthu Sendhil Kumaran & Davinder Parsad. (2019) Intravenous cyclosporine in treatment of Stevens–Johnson syndrome/toxic epidermal necrolysis: A case series. Dermatologic Therapy, pages e12957.
Crossref
Sophie E. Berends, Anne S. Strik, Mark Löwenberg, Geert R. D’Haens & Ron A. A. Mathôt. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics 58:1, pages 15-37.
Crossref
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
E. G. Quetglas, A. Armuzzi, S. Wigge, G. Fiorino, L. Barnscheid, M. Froelich & Silvio Danese. (2015) Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. European Journal of Clinical Pharmacology 71:7, pages 773-799.
Crossref
A. Schrauder, S. Saleh, K. W. Sykora, H. Hoy, K. Welte, J. Boos, G. Hempel & L. Grigull. (2009) Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. Pediatric Transplantation 13:4, pages 444-450.
Crossref
Robert J. Greenstein, Liya Su, Ramon A. Juste & Sheldon T. Brown. (2008) On the Action of Cyclosporine A, Rapamycin and Tacrolimus on M. avium Including Subspecies paratuberculosis. PLoS ONE 3:6, pages e2496.
Crossref
Laurence J. Egan & William J. Sandborn. 2005. Inflammatory Bowel Disease: From Bench to Bedside. Inflammatory Bowel Disease: From Bench to Bedside 495 521 .
Conor G Loftus, Laurence J Egan & William J Sandborn. (2004) Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterology Clinics of North America 33:2, pages 141-169.
Crossref
Laurence J. Egan & William J. Sandborn. 2003. Inflammatory Bowel Disease: From Bench to Bedside. Inflammatory Bowel Disease: From Bench to Bedside 495 521 .
G. Wu & S-M. Yan. (2001) Cyclosporine therapeutic and toxic effects may be related to different cyclosporine concentration zones in plasma. Medical Hypotheses 56:5, pages 691-692.
Crossref
Matthias Schwab & Ulrich Klotz. (2001) Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 40:10, pages 723-751.
Crossref
A. C. F. Taylor, W. R. Connell, R. Elliott & A. J. F. D'Apice. (2008) Oral cyclosporin in refractory inflammatory bowel disease. Australian and New Zealand Journal of Medicine 28:2, pages 179-183.
Crossref
Laurence J Egan, William J Sandborn & William J Tremaine. (1998) Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine. American Journal of Gastroenterology 93:3, pages 442-448.
Crossref
E. ELTON & S. B. HANAUER. (2007) Review article: The medical management of Crohn's disease. Alimentary Pharmacology & Therapeutics 10:1, pages 1-22.
Crossref
Robert J. Greenstein & Adrian J. Greenstein. (1995) Is there clinical, epidemiological and molecular evidence for two forms of Crohn's disease?. Molecular Medicine Today 1:7, pages 343-348.
Crossref
William J. Sandborn. (1995) Cyclosporine therapy for inflammatory bowel disease: Definitive answers and remaining questions. Gastroenterology 109:3, pages 1001-1003.
Crossref
Simone S. Flückiger, Christoph Schmidt, Ansgar Meyer, Zoltan Kallay, Atholl Johnston & Klaus Kutz. (2013) Pharmacokinetics of Orally Administered Cyclosporine in Patients with Crohn's Disease. The Journal of Clinical Pharmacology 35:7, pages 681-687.
Crossref
William J. Sandborn. (1995) A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 1:1, pages 48-63.
Crossref
A. B. R. Thomson. 1994. Inflammatory Bowel Disease. Inflammatory Bowel Disease 385 423 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.